Literature DB >> 26123318

Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer.

Qunying Lin1, Lijing Guo1, Guosheng Lin1, Zhiwei Chen1, Tonghuan Chen1, Juan Lin1, Bo Zhang2, Xiaobin Gu3.   

Abstract

BACKGROUND: Osteopontin (OPN) and vascular endothelial growth factor (VEGF) play important roles in cancer progression and angiogenesis. In the current study we aimed to investigate the clinical significance of OPN and VEGF expression in patients with non-small-cell lung cancer (NSCLC) and to investigate their prognostic value for NSCLC.
METHODS: Immunohistochemical staining was used to detect the expression of OPN and VEGF in 146 NSCLC patients undergoing surgical resection in our hospital between 2006 and 2008. The associations between OPN and VEGF expression and clinicopathological data were analyzed using chi-square test analysis. Survival analysis was performed using the Kaplan-Meier method. The prognostic values of OPN and VEGF were evaluated by univariate and multivariate Cox proportional hazard model analysis.
RESULTS: OPN and VEGF expression was positive in 94 and 86 out of 146 NSCLC specimens, respectively. OPN expression was significantly associated with gender (P=0.002), TNM stage (P<0.001) and tumor differentiation (P=0.008). VEGF expression was significantly associated with TNM stage (P=0.015), tumor differentiation (P=0.032) and lymph-node status (P<0.001). There was a significant correlation between OPN and VEGF expression (P=0.035). Survival analysis indicated that OPN(+)/VEGF(+) patients had the worst prognosis. Furthermore, univariate and multivariate analysis suggested that tumor stage, lymph-node metastases, OPN expression and VEGF expression were independent prognostic factors for NSCLC.
CONCLUSION: The data suggest that OPN and VEGF expressions could serve as prognostic factors for NSCLC.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Non-small cell lung cancer; Osteopontin; Prognosis; Survival; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2015        PMID: 26123318     DOI: 10.1016/j.canep.2015.05.010

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  20 in total

1.  Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer.

Authors:  Joseph M Chan; Álvaro Quintanal-Villalonga; Vianne Ran Gao; Yubin Xie; Viola Allaj; Ojasvi Chaudhary; Ignas Masilionis; Jacklynn Egger; Andrew Chow; Thomas Walle; Marissa Mattar; Dig V K Yarlagadda; James L Wang; Fathema Uddin; Michael Offin; Metamia Ciampricotti; Besnik Qeriqi; Amber Bahr; Elisa de Stanchina; Umesh K Bhanot; W Victoria Lai; Matthew J Bott; David R Jones; Arvin Ruiz; Marina K Baine; Yanyun Li; Natasha Rekhtman; John T Poirier; Tal Nawy; Triparna Sen; Linas Mazutis; Travis J Hollmann; Dana Pe'er; Charles M Rudin
Journal:  Cancer Cell       Date:  2021-10-14       Impact factor: 31.743

2.  Sesquiterpene from Polygonum barbatum disrupts mitochondrial membrane potential to induce apoptosis and inhibits metastasis by downregulating matrix metalloproteinase and osteopontin in NCI-H460 cells.

Authors:  Binte Zehra; Ayaz Ahmed; Ajmal Khan; Afshan Shams; Reaz Uddin; Sidra Rafi; Taseer Ahmed Khan; Umar Farooq; Syed Abid Ali
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-05-23       Impact factor: 3.195

3.  Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer.

Authors:  Ryota Shibaki; Shuji Murakami; Yuki Shinno; Yuji Matsumoto; Tatsuya Yoshida; Yasushi Goto; Shintaro Kanda; Hidehito Horinouchi; Yutaka Fujiwara; Nobuyuki Yamamoto; Noboru Yamamoto; Yuichiro Ohe
Journal:  Cancer Immunol Immunother       Date:  2020-03-10       Impact factor: 6.968

4.  Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation.

Authors:  Yu-Jin Wang; Qing-Wen Wang; Dong-Hu Yu; Cong-Kuan Song; Zi-Xin Guo; Xiao-Ping Liu; Chen Chen; Jie Yao; Ai-Fen Wang; Wei-Dong Hu
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-13       Impact factor: 4.553

5.  Identification of urine biomarkers associated with lung adenocarcinoma.

Authors:  Weiwei Wang; Shanshan Wang; Man Zhang
Journal:  Oncotarget       Date:  2017-06-13

Review 6.  Human osteopontin: Potential clinical applications in cancer (Review).

Authors:  Chengcheng Hao; Yuxin Cui; Sionen Owen; Wenbin Li; Shan Cheng; Wen G Jiang
Journal:  Int J Mol Med       Date:  2017-04-21       Impact factor: 4.101

7.  Delisheng induces antiproliferation and apoptosis effects in Hep3B cells via modulation of angiogenic proteins.

Authors:  Hai-Feng Sun; Li Jing; Tao Wu; Ming Li; Ya-Huan Guo; Hui Guo; Zheng Zhao; Min-Cong Wang; Shu-Hong Wang; Ke-Jun Nan
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

Review 8.  The role of osteopontin in the progression of solid organ tumour.

Authors:  Hailin Zhao; Qian Chen; Azeem Alam; Jiang Cui; Ka Chun Suen; Aurelie Pac Soo; Shiori Eguchi; Jianteng Gu; Daqing Ma
Journal:  Cell Death Dis       Date:  2018-03-02       Impact factor: 8.469

9.  Osteopontin promotes cancer cell drug resistance, invasion, and lactate production and is associated with poor outcome of patients with advanced non-small-cell lung cancer.

Authors:  Xiaoping Ouyang; Yumin Huang; Xing Jin; Wei Zhao; Tao Hu; Feng Wu; Jianan Huang
Journal:  Onco Targets Ther       Date:  2018-09-19       Impact factor: 4.147

10.  Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?

Authors:  Vasiliki Petta; Stelios Loukides; Konstantinos Kostikas; Andriana I Papaioannou; Georgios Papatheodorou; Kyriaki Cholidou; Ioannis Tomos; Spyridon Papiris; Nikolaos G Koulouris; Petros Bakakos
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.